Innovus Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on
Tuesday, November 14, 2017
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (OTCQB: INNV), today announced that the Company will release its third quarter
2017 financial results and provide a corporate update on Tuesday, November 14, 2017, after the close of the U.S. financial markets.
The Company will host a conference call at 4:15 p.m. ET/1:15 p.m. PT on the same day to discuss the financial results and recent
business developments.
To participate in the call, please dial 1-877-883-0383 for domestic callers or 1-412-902-6506 for international
callers. Participant Elite Entry Number: 5606897. A replay of the call will be available for 30 days. To access the
replay, dial 1-877-344-7529 domestically or 1-412-317-0088 internationally and reference Conference ID: 10113950. The replay will
be available shortly after the end of the conference call.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve
men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and
packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial
partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our
on-line channels, retailers and wholesalers. The Company is dedicated to be a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products, men’s and women’s health supplements, related diagnostics and medical
devices. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change
from prescription (or Rx) to OTC, as well as related products.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.fluticare.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.allervarx.com; and www.apeaz.com.
Innovus Pharma’s Forward-Looking Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information
contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties
that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its financial results, projected revenues, projected online subscribers and other
customers, estimated markets for its products, and statements about achieving its other corporate and business development, growth,
commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to
read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly
reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or
without charge from the Company.
Emerging Markets Consulting, LLC
James S. Painter, III, 407-340-0026
jamespainter@emergingmarketsllc.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20171106005982/en/